Somewhat Favorable News Coverage Somewhat Unlikely to Impact Hutchison China MediTech Limited (HCM) Share Price
News articles about Hutchison China MediTech Limited (NASDAQ:HCM) have been trending somewhat positive this week, Accern Sentiment reports. The research firm identifies negative and positive news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Hutchison China MediTech Limited earned a media sentiment score of 0.13 on Accern’s scale. Accern also gave media coverage about the company an impact score of 44.719479224936 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the headlines that may have effected Accern Sentiment’s analysis:
- Chi-Med Initiates FRUTIGA, a Phase III Trial of Fruquintinib in Second-Line Gastric Cancer (advfn.com)
- Hutchison China MediTech (HCM) Initiates FRUTIGA Phase III Trial of Fruquintinib in Second-Line Gastric Cancer (streetinsider.com)
- Hutchison China MediTech : Chi Med Initiates FRUTIGA, a Phase III Trial of Fruquintinib in Second-Line Gastric Cancer (4-traders.com)
- Chi-Med Initiates FRUTIGA, a Phase III Trial of Fruquintinib in Second-Line Gastric Cancer (finance.yahoo.com)
- Week In Review: China Resources Pharma Files For $369 Million China Life Science Investment Fund (seekingalpha.com)
Hutchison China MediTech Limited (HCM) opened at $29.57 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 1.84 and a quick ratio of 1.73.
HCM has been the topic of a number of analyst reports. BidaskClub raised Hutchison China MediTech Limited from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 5th. Canaccord Genuity set a $30.00 price target on Hutchison China MediTech Limited and gave the stock a “buy” rating in a research note on Monday, July 31st.
COPYRIGHT VIOLATION WARNING: This news story was originally published by Watch List News and is owned by of Watch List News. If you are viewing this news story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://www.watchlistnews.com/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-hutchison-china-meditech-limited-hcm-share-price/1677605.html.
About Hutchison China MediTech Limited
Hutchison China MediTech Limited (Chi-Med) is a China-based, globally-focused healthcare group. The Company researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform focuses on discovering and developing therapeutics in oncology and autoimmune diseases for the global market.
Receive News & Ratings for Hutchison China MediTech Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hutchison China MediTech Limited and related companies with Analyst Ratings Network's FREE daily email newsletter.